F 17464

Drug Profile

F 17464

Alternative Names: F17464

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Pierre Fabre
  • Class Antipsychotics
  • Mechanism of Action Dopamine D3 receptor antagonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Schizophrenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia(In volunteers) in USA (PO, Capsule)
  • 01 Dec 2015 Pierre Fabre Medicament completes a phase II trial in Schizophrenia in France, Hungary, Latvia, Romania and Russia (NCT02151656)
  • 01 Jun 2014 Phase-II clinical trials in Schizophrenia in France and Latvia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top